Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Adds Penn Medicine Site as Phase 3 Enrollment Accelerates Toward H1 2026 Readout

By The Northwire Desk — AI Analysis May 13, 2026 · 07:30 BCT · 5.58 BRIACELL THERAPEUTICS CORP. J
Executive Summary
  • Event: Addition of a new clinical trial site (Penn Medicine's Abramson Cancer Center) to the pivotal Phase 3 Bria-ABC study.
  • Study Details: Evaluating Bria-IMT™ combined with an immune checkpoint inhibitor against physician's choice for advanced metastatic breast cancer.
  • Regulatory Status: FDA Fast Track designation remains active.
  • Enrollment Context: Follows the May 12, 2026 announcement that enrollment surpassed 230 patients (out of >315 screened).
  • Interim Analysis Trigger: The study will trigger an interim analysis once 144 patient events (deaths) occur.
  • Timeline: Interim topline data is anticipated in the first half of 2026, consistent with previous guidance.
Material Impact
  • Incremental Progress: The addition of a major academic site like Penn Medicine supports enrollment velocity but does not alter the fundamental risk/reward profile of the Phase 3 readout itself.
  • Expectation Alignment: This news is in line with the May 12, 2026 update regarding enrollment momentum and the Nature Medicine feature highlighting the trial's significance. The market likely anticipated site expansions to meet H1 2026 data targets.
  • No New Catalysts: Unlike a regulatory approval or a major financing event (such as the $30M offering in January), this is operational maintenance news required for trial execution.
  • Risk Mitigation: Continued site activation reduces the risk of enrollment delays, which could otherwise push data readouts beyond H1 2026 and increase cash burn concerns.
BCT · Price
Company Overview
  • Company: BriaCell Therapeutics Corp. focuses on personalized cancer immunotherapies.
  • Flagship Project: Bria-IMT™ in combination with an immune checkpoint inhibitor (CPI) for metastatic breast cancer (Phase 3).
  • Secondary Pipeline: Bria-BRES+ (Breast Cancer), Bria-PROS+ (Prostate Cancer), and Bria-OTS+ platform.
  • Regulatory Status: FDA Fast Track designation for the Phase 3 regimen.
  • Clinical Evidence: Previous Phase 2 data showed extended survival (>18 months) in heavily pretreated patients compared to historical benchmarks (~9-10 months).
Read the original news release →

More from BRIACELL THERAPEUTICS CORP. J

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other